Programs on mobility, status of follow-up and CD(4)(+)T cell testing among people living with HIV/AIDS, in China 2011-2015.
10.3760/cma.j.issn.0254-6450.2018.06.008
- Author:
J HAN
1
;
H L TANG
;
J LI
;
Y R MAO
Author Information
1. Division of Integration and Evaluation, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
- Publication Type:Journal Article
- Keywords:
CD(4)(+)T cell count test;
Follow-up;
Mobility;
People living with HIV/AIDS
- MeSH:
Adult;
Anti-HIV Agents/therapeutic use*;
CD4 Lymphocyte Count;
China/epidemiology*;
Follow-Up Studies;
HIV Infections/immunology*;
Humans
- From:
Chinese Journal of Epidemiology
2018;39(6):732-738
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the mobility, status of follow-up and CD(4)(+)T cell testing (CD(4) testing) programs among people living with HIV (PLHIV) between 2011 and 2015 and to improve the prevention program on HIV secondary transmission. Methods: Data were collected from both Case Reporting Cards and Follow-up Cards through the National HIV/AIDS Comprehensive Control and Prevention data system. Changes of residence among the newly reported cases and survival cases between 2011 and 2015 were analyzed by SPSS 24.0 software. Results: The number of newly reported inter-provincial mobile PLHIV had been increasing, with proportions of the total reported cases from 10.0% (5 576/55 805) in 2011 to 13.3% (15 348/115 231) in 2015. After adjusting for related confounders, percentages of follow-up and CD(4) testing were lower in inter-provincial and inter-prefectural mobile cases than those without. Conclusion: Service regarding the follow-up and CD(4) testing programs was affected by mobility of people living with HIV/AIDS. Programs on communication and personal contact should be strengthened in the follow-up management services for PLHIV. Information on potential mobility of PLHIV should be gathered timely by health workers during the subsequent follow-up period to avoid the loss of follow-up and CD(4) testing on patients.
